{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T03:15:08Z","timestamp":1783480508652,"version":"3.55.0"},"reference-count":238,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001807","name":"State of Sao Paulo Research Foundation","doi-asserted-by":"publisher","award":["2024\/02915-0"],"award-info":[{"award-number":["2024\/02915-0"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"State of Sao Paulo Research Foundation","doi-asserted-by":"publisher","award":["2024\/00989-7"],"award-info":[{"award-number":["2024\/00989-7"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"State of Sao Paulo Research Foundation","doi-asserted-by":"publisher","award":["2024\/20799-8"],"award-info":[{"award-number":["2024\/20799-8"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"publisher","award":["440398\/2022-3"],"award-info":[{"award-number":["440398\/2022-3"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"publisher","award":["442690\/2020-7"],"award-info":[{"award-number":["442690\/2020-7"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biotechnology Advances"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.biotechadv.2026.108942","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T15:58:58Z","timestamp":1780329538000},"page":"108942","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["CAR-T cells and cancer nanovaccines: Comparative insights into advances and translational challenges"],"prefix":"10.1016","volume":"91","author":[{"given":"Gabriel","family":"de Camargo Zaccariotto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valtencir","family":"Zucolotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biotechadv.2026.108942_bb0005","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.omto.2020.03.018","article-title":"Viral delivery of CAR targets to solid tumors enables effective cell Therapy","volume":"17","author":"Aalipour","year":"2020","journal-title":"Mol. Ther. - Oncol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0010","article-title":"1202 in vivo engineering of CAR T cells using a novel targeted LNP-mRNA technology","volume":"11","author":"Adams","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0015","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1671761","article-title":"In vivo generated human CAR T cells eradicate tumor cells","volume":"8","author":"Agarwal","year":"2019","journal-title":"OncoImmunology"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0020","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.3390\/cancers12071826","article-title":"Advances in anti-Cancer immunotherapy: Car-T cell, checkpoint inhibitors, dendritic cell vaccines, and oncolytic viruses, and emerging cellular and molecular targets","volume":"12","author":"Alard","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0025","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","article-title":"CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn","volume":"21","author":"Albelda","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1432799","article-title":"ReCARving the future: bridging CAR T-cell therapy gaps with synthetic biology, engineering, and economic insights","volume":"15","author":"Ali","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0035","article-title":"The CONCORD\u2013lancet global commission on Cancer","volume":"0","author":"Allemani","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0040","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1007\/s00262-023-03443-1","article-title":"Cytotoxicity of CD19-CAR-NK92 cells is primarily mediated via perforin\/granzyme pathway","volume":"72","author":"Althaus","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0045","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41392-026-02710-8","article-title":"Immune modulatory vaccines targeting tumor microenvironment antigens: recent advances in oncology and beyond","volume":"11","author":"Andersen","year":"2026","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0050","series-title":"Targeted In Vivo Generation of CAR T and NK Cells Utilizing an Engineered Lentiviral Vector Platform. Blood, 65th ASH Annual Meeting Abstracts","first-page":"763","volume":"142","author":"Andorko","year":"2023"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0055","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1016\/j.cell.2024.07.016","article-title":"LAG-3 and PD-1 synergize on CD8+ T cells to drive T cell exhaustion and hinder autocrine IFN-\u03b3-dependent anti-tumor immunity","volume":"187","author":"Andrews","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0060","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150807","article-title":"CAR T cell manufacturing from naive\/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome","volume":"132","author":"Arcangeli","year":"2022","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0065","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1038\/s41586-022-04772-4","article-title":"A vaccine targeting resistant tumours by dual T cell plus NK cell attack","volume":"606","author":"Badrinath","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0070","article-title":"Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13R\u03b12 in recurrent glioblastoma: a phase 1 trial","volume":"1\u201310","author":"Bagley","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0075","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41577-024-01091-9","article-title":"Vax-innate: improving therapeutic cancer vaccines by modulating T cells and the tumour microenvironment","volume":"25","author":"Baharom","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0080","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1295257","article-title":"Tumor-associated macrophages: an effective player of the tumor microenvironment","volume":"14","author":"Basak","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0085","first-page":"629","article-title":"Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients","volume":"2","author":"Biasco","year":"2021","journal-title":"Nat. Can."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0090","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3390\/vaccines9020097","article-title":"An update on self-amplifying mRNA vaccine development","volume":"9","author":"Blakney","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0095","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining \u2018T cell exhaustion.\u2019","volume":"19","author":"Blank","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0100","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0105","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3390\/ph14030236","article-title":"Regulation of MHC I molecules in glioblastoma cells and the sensitizing of NK cells","volume":"14","author":"Burster","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0110","unstructured":"Cancer Vaccines Market Growth, Drivers, and Opportunities [WWW Document], n.d. MarketsandMarkets. URL https:\/\/www.marketsandmarkets.com\/Market-Reports\/cancer-vaccines-market-30645011.html (accessed 2.12.25)."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0115","unstructured":"CAR T-cell Therapy Market Growth, Drivers, and Opportunities [WWW Document], n.d. MarketsandMarkets. URL https:\/\/www.marketsandmarkets.com\/Market-Reports\/car-t-cell-therapy-market-47772841.html (accessed 2.12.25)."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0120","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00482","article-title":"Point-of-care CAR T-cell production (ARI-0001) using a closed semi-automatic bioreactor: experience from an academic phase I clinical trial","volume":"11","author":"Castella","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0125","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/s41422-022-00745-4","article-title":"Off-the-shelf CAR T cells to treat cancer","volume":"32","author":"Castelli","year":"2022","journal-title":"Cell Res."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2019.151899","article-title":"Mechanistic basis of co-stimulatory CD40-CD40L ligation mediated regulation of immune responses in cancer and autoimmune disorders","volume":"225","author":"Chand Dakal","year":"2020","journal-title":"Immunobiology"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0135","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s44222-022-00004-6","article-title":"Biomaterials tools to modulate the tumour microenvironment in immunotherapy","volume":"1","author":"Chao","year":"2023","journal-title":"Nat. Rev. Bioeng."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0140","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2307800120","article-title":"Endosomal escape: a bottleneck for LNP-mediated therapeutics","volume":"121","author":"Chatterjee","year":"2024","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0145","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719841581","article-title":"CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products","volume":"10","author":"Chavez","year":"2019","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0150","doi-asserted-by":"crossref","first-page":"4819","DOI":"10.1038\/s41467-025-59904-x","article-title":"Durable response to CAR T is associated with elevated activation and clonotypic expansion of the cytotoxic native T cell repertoire","volume":"16","author":"Cheloni","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0155","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14235983","article-title":"Efficacy, safety, and challenges of CAR T-cells in the treatment of solid tumors","volume":"14","author":"Chen","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0160","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009716","article-title":"Durable antitumor response via an oncolytic virus encoding decoy-resistant IL-18","volume":"12","author":"Cheng","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0165","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","article-title":"Universal chimeric antigen receptors for multiplexed and logical control of T cell responses","volume":"173","author":"Cho","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0170","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe7378","article-title":"SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma","volume":"13","author":"Choe","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0175","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","article-title":"Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma","volume":"390","author":"Choi","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0180","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","article-title":"Clinical implications of T cell exhaustion for cancer immunotherapy","volume":"19","author":"Chow","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0185","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_397912","article-title":"High cost of chimeric antigen receptor T-cells: challenges and solutions","author":"Cliff","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0190","series-title":"FDA Approval Brings First Gene Therapy to the United States [WWW Document]","author":"Commissioner, O. of the","year":"2020"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0195","series-title":"FDA Approves CAR-T Cell Therapy to Treat Adults with Certain Types of Large B-cell Lymphoma [WWW Document]","author":"Commissioner, O. of the","year":"2020"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0200","series-title":"FDA Approves First Cell-Based Gene Therapy for Adult Patients with Relapsed or Refractory MCL [WWW Document]","author":"Commissioner, O. of the","year":"2020"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0205","series-title":"FDA Eliminates Risk Evaluation and Mitigation Strategies (REMS) for Autologous Chimeric Antigen Receptor CAR T cell Immunotherapies [WWW Document]","author":"Commissioner, O. of the","year":"2025"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115973","article-title":"CAR-T cells containing CD28 versus 4-1BB co-stimulatory domains show distinct metabolic profiles in patients","volume":"44","author":"Cook","year":"2025","journal-title":"Cell Rep."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0215","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy","volume":"1\u201312","author":"Cordas dos Santos","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0220","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1038\/s41590-023-01659-y","article-title":"Forks in the road for CAR T and CAR NK cell cancer therapies","volume":"24","author":"Dagher","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0230","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1080\/14760584.2021.1984890","article-title":"Nanovaccine: an emerging strategy","volume":"20","author":"Das","year":"2021","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0235","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0240","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41577-020-0390-6","article-title":"A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion","volume":"21","author":"Dersh","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0245","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.636568","article-title":"Cancer immune evasion through loss of MHC class I antigen presentation","volume":"12","author":"Dhatchinamoorthy","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0250","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkae059","article-title":"Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas","volume":"8","author":"Di","year":"2024","journal-title":"JNCI Cancer Spectr."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0255","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41586-024-07300-8","article-title":"FOXO1 is a master regulator of memory programming in CAR T cells","volume":"629","author":"Doan","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0260","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/d41586-024-01717-x","article-title":"How personalized cancer vaccines could keep tumours from coming back","volume":"630","author":"Dolgin","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0265","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1038\/d41586-024-00841-y","article-title":"How does a cancer vaccine work?","volume":"627","author":"Drew","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2025.03.019","article-title":"Immunophenotype of CAR T-cells and associated apheresis products predicts clinical response in a single-center CD22 CAR T-cell therapy trial in B-cell acute lymphoblastic leukemia","author":"Dreyzin","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0275","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1038\/s41591-024-03231-z","article-title":"CAR-T and cellular gene therapies are too expensive","volume":"30","author":"Dropuli\u0107","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0280","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/2159-8290.CD-18-1090","article-title":"Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition","volume":"9","author":"Ennishi","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0285","doi-asserted-by":"crossref","first-page":"12261","DOI":"10.1021\/acs.jmedchem.1c00896","article-title":"Synthetic glycolipids as molecular vaccine adjuvants: mechanism of action in human cells and in vivo activity","volume":"64","author":"Facchini","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0290","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2403227121","article-title":"Successful use of anti-CD19 CAR T cells in severe treatment-refractory stiff-person syndrome","volume":"121","author":"Faissner","year":"2024","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0295","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jconrel.2024.07.052","article-title":"Physicochemical and structural insights into lyophilized mRNA-LNP from lyoprotectant and buffer screenings","volume":"373","author":"Fan","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0300","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/s41420-023-01626-4","article-title":"Recombinant oncolytic adenovirus armed with CCL5, IL-12, and IFN-\u03b3 promotes CAR-T infiltration and proliferation in vivo to eradicate local and distal tumors","volume":"9","author":"Fang","year":"2023","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0305","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12916-016-0623-5","article-title":"Cancer immunotherapy: the beginning of the end of cancer?","volume":"14","author":"Farkona","year":"2016","journal-title":"BMC Med."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0310","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/ajh.25418","article-title":"An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer","volume":"94","author":"Feins","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0315","article-title":"Albumin-recruiting lipid nanoparticle potentiates the safety and efficacy of mRNA vaccines by avoiding liver accumulation","volume":"1\u201314","author":"Feng","year":"2025","journal-title":"Nat. Mater."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0320","article-title":"Cancer-fighting CAR T cells show promising results for hard-to-treat tumours","author":"Fieldhouse","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2024.03.002","article-title":"CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis","volume":"5","author":"Fischbach","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0330","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41586-025-09873-4","article-title":"Transient hepatic reconstitution of trophic factors enhances aged immunity","volume":"650","author":"Friedrich","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0335","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1080\/14712598.2022.2086043","article-title":"Bispecific CAR T-cells for B-cell malignancies","volume":"22","author":"Furqan","year":"2022","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0340","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/bloodadvances.2023011168","article-title":"Maintenance therapy for early loss of B-cell aplasia after anti-CD19 CAR T-cell therapy","volume":"8","author":"Gabelli","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2026.120115","article-title":"The role of cytokines in cytokine release syndrome (CRS) after CAR T cell therapy","volume":"1873","author":"Gabriel","year":"2026","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Cell Res."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0350","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201701429","article-title":"Erythrocyte-membrane-enveloped perfluorocarbon as nanoscale artificial red blood cells to relieve tumor hypoxia and enhance cancer radiotherapy","volume":"29","author":"Gao","year":"2017","journal-title":"Adv. Mater."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0355","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1093\/jnci\/djab194","article-title":"Epigenetic profiling and response to CD19 chimeric antigen receptor T-cell Therapy in B-cell malignancies","volume":"114","author":"Garcia-Prieto","year":"2022","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2026.03.047","article-title":"Distinct in vivo dynamics of donor-derived stem cell memory CAR T cells post-allogeneic HSCT relapse","author":"Gattinoni","year":"2026","journal-title":"Cell"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0365","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411803","article-title":"CAR-T state of the art and future challenges, a regulatory perspective","volume":"24","author":"Giorgioni","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0370","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12951-021-00805-8","article-title":"Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles","volume":"19","author":"Gong","year":"2021","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0375","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1038\/s41563-023-01646-6","article-title":"In situ PEGylation of CAR T cells alleviates cytokine release syndrome and neurotoxicity","volume":"22","author":"Gong","year":"2023","journal-title":"Nat. Mater."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0380","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41573-024-00974-9","article-title":"Enhancing in situ cancer vaccines using delivery technologies","volume":"23","author":"Gong","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0385","article-title":"Tumour-derived small extracellular vesicles act as a barrier to therapeutic nanoparticle delivery","volume":"1\u201312","author":"Gong","year":"2024","journal-title":"Nat. Mater."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0390","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-025-01097-x","article-title":"Recent advances and perspectives on the development of circular RNA cancer vaccines","volume":"10","author":"Gong","year":"2025","journal-title":"Npj Vaccines"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0395","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.ccell.2024.05.005","article-title":"RNA vaccines for cancer: principles to practice","volume":"42","author":"Guasp","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0400","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3390\/bioengineering7030111","article-title":"Biomimetic nanocarriers for cancer target therapy","volume":"7","author":"Guido","year":"2020","journal-title":"Bioengineering"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0405","article-title":"Immune-remodeling mRNAs expressing IRF8 or NIK generate durable antitumor immunity in multiple cancer models","volume":"1\u201316","author":"Gupta","year":"2026","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0410","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","article-title":"Risk of second tumors and T-cell lymphoma after CAR T-cell Therapy","volume":"390","author":"Hamilton","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.109887","article-title":"Nanovaccines for cancer immunotherapy: focusing on complex formation between adjuvant and antigen","volume":"117","author":"Hashemi Goradel","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0420","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12943-024-02208-3","article-title":"Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy","volume":"24","author":"He","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0425","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2209260120","article-title":"Extracellular matrix physical properties govern the diffusion of nanoparticles in tumor microenvironment","volume":"120","author":"He","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0430","article-title":"T cell competition in multi-neoantigen cancer vaccines","volume":"1\u20131","author":"Hoos","year":"2026","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0435","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41573-021-00189-2","article-title":"Navigating CAR-T cells through the solid-tumour microenvironment","volume":"20","author":"Hou","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0440","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-020-00910-5","article-title":"Recent advances in CAR-T cell engineering","volume":"13","author":"Huang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0445","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1126\/science.ads8473","article-title":"In vivo CAR T cell generation to treat cancer and autoimmune disease","volume":"388","author":"Hunter","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0465","article-title":"Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies","volume":"1\u201311","author":"Jadlowsky","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0470","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.622509","article-title":"Exhausted CD8+T cells in the tumor immune microenvironment: new pathways to Therapy","volume":"11","author":"Jiang","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0475","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41551-022-00875-5","article-title":"CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers","volume":"6","author":"Jin","year":"2022","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0480","article-title":"mRNA vaccines engage unconventional pathways in CD8+ T cell priming","volume":"1\u201310","author":"Jo","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0485","series-title":"Poor Hematopoietic Reserve at the Time of CD19 CAR T-Cell Infusion Is Associated with Long Term B-Cell Aplasia. Blood, 65th ASH Annual Meeting Abstracts","first-page":"3512","volume":"142","author":"Johnson","year":"2023"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0490","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.cell.2007.01.029","article-title":"The epigenomics of cancer","volume":"128","author":"Jones","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0495","series-title":"Spain, A Hospital Brews its Own","article-title":"In the U.S., scientists see barriers to the development of CAR-T cell therapies","author":"Joseph","year":"2023"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0500","series-title":"Ionizable Cationic Lipids and Lipid Nanoparticles","author":"Karmali","year":"2023"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0505","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0510","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00262-024-03817-z","article-title":"Breaking the shield of solid tumors: a combined approach for enhanced efficacy of CAR-T cells","volume":"74","author":"Khaliulin","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0515","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(24)00424-0","article-title":"CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis","volume":"403","author":"Krickau","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0520","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.trecan.2025.08.009","article-title":"Overcoming solid-tumor barriers: armored CAR-T cell therapy","volume":"11","author":"Kwon","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0525","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/s41590-020-0676-7","article-title":"Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity","volume":"21","author":"Lai","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0530","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202211420","article-title":"Optimizing lipid nanoparticles for delivery in primates","volume":"35","author":"Lam","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0535","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/s41577-025-01229-3","article-title":"Microenvironmental regulation of solid tumour resistance to CAR T cell therapy","volume":"26","author":"Lamplugh","year":"2026","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0540","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41416-025-03075-5","article-title":"Spatial omics technology potentially promotes the progress of tumor immunotherapy","volume":"133","author":"Lan","year":"2025","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0545","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/d41586-025-00507-3","article-title":"Woman in cancer remission for record 19 years after CAR-T immune treatment","volume":"638","author":"Ledford","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0550","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0555","doi-asserted-by":"crossref","DOI":"10.3389\/or.2025.1617487","article-title":"Fibroblast activation protein and the tumour microenvironment: challenges and therapeutic opportunities","volume":"19","author":"Lee","year":"2025","journal-title":"Oncol. Rev."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0560","article-title":"The phase 3 INTerpath-002 study design: individualized neoantigen therapy (INT) V940 (mRNA-4157) plus pembrolizumab vs placebo plus pembrolizumab for resected early-stage non\u2013small-cell lung cancer (NSCLC)","volume":"42","author":"Lee","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0565","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.00672","article-title":"Resistance mechanisms of anti-PD1\/PDL1 therapy in solid tumors","volume":"8","author":"Lei","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0570","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2024.1426129","article-title":"Understanding the impact of in vitro transcription byproducts and contaminants","volume":"11","author":"Lenk","year":"2024","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0575","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","article-title":"Unanswered questions following reports of secondary malignancies after CAR-T cell therapy","volume":"30","author":"Levine","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0580","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1021\/acs.nanolett.1c00168","article-title":"Platelet-membrane-coated nanoparticles enable vascular disrupting agent combining anti-Angiogenic drug for improved tumor vessel impairment","volume":"21","author":"Li","year":"2021","journal-title":"Nano Lett."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0585","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12943-020-01234-1","article-title":"Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects","volume":"19","author":"Li","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0590","article-title":"Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma","volume":"1\u20135","author":"Li","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0595","doi-asserted-by":"crossref","first-page":"50734","DOI":"10.1021\/acsami.0c14909","article-title":"Multifunctional nanoparticles boost cancer immunotherapy based on modulating the immunosuppressive tumor microenvironment","volume":"12","author":"Li","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0600","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s40164-024-00549-9","article-title":"The next frontier in immunotherapy: potential and challenges of CAR-macrophages","volume":"13","author":"Li","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0605","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.766","article-title":"Circulating tumor DNA methylation detection as biomarker and its application in tumor liquid biopsy: advances and challenges","volume":"5","author":"Li","year":"2024","journal-title":"MedComm"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0610","article-title":"Tumor extracellular matrix modulating strategies for enhanced antitumor therapy of nanomedicines","volume":"16","author":"Li","year":"2022","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0615","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12943-024-02032-9","article-title":"A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy","volume":"23","author":"Li","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0620","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/7530794","article-title":"Radiotherapy\/chemotherapy-immunotherapy for cancer management: from mechanisms to clinical implications","volume":"2023","author":"Li","year":"2023","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0625","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1038\/s41467-023-38573-8","article-title":"Molecular basis of differential HLA class I-restricted T cell recognition of a highly networked HIV peptide","volume":"14","author":"Li","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0630","article-title":"CAR-X cell engineering","volume":"1\u201321","author":"Li","year":"2026","journal-title":"Nat. Rev. Bioeng."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0635","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s12951-023-01977-1","article-title":"Targeting lymph node delivery with nanovaccines for cancer immunotherapy: recent advances and future directions","volume":"21","author":"Li","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0640","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1038\/s41467-025-59977-8","article-title":"Neoantigen enriched biomimetic nanovaccine for personalized cancer immunotherapy","volume":"16","author":"Li","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0645","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.tips.2024.07.005","article-title":"Frontiers in CAR-T cell therapy for autoimmune diseases","volume":"45","author":"Li","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0665","author":"Liu"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0670","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0675","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s13238-020-00707-9","article-title":"Memory T cells: strategies for optimizing tumor immunotherapy","volume":"11","author":"Liu","year":"2020","journal-title":"Protein Cell"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0680","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-024-03334-7","article-title":"Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial","volume":"31","author":"Lopez","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0685","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41568-024-00785-5","article-title":"Cross-priming in cancer immunology and immunotherapy","volume":"25","author":"Luri-Rey","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0690","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41408-025-01260-6","article-title":"Donor-derived CARCIK-CD19 cells engineered with sleeping beauty transposon in acute lymphoblastic leukemia relapsed after allogeneic transplantation","volume":"15","author":"Lussana","year":"2025","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0695","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41577-021-00554-7","article-title":"Modulation of immune responses to vaccination by the microbiota: implications and potential mechanisms","volume":"22","author":"Lynn","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0700","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0705","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","article-title":"CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial","volume":"29","author":"Mackensen","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0710","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17111882","article-title":"Current progress and future perspectives of RNA-based cancer vaccines: a 2025 update","volume":"17","author":"Magoola","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0715","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS2679","article-title":"Binary oncolytic adenovirus in combination with HER2-specific autologous CAR VST for treatment of advanced HER2-positive solid tumors (VISTA)","volume":"42","author":"Makawita","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0720","article-title":"mRNA vaccine immunity is enhanced by hepatocyte detargeting and not dependent on dendritic cell expression","volume":"1\u201315","author":"Marks","year":"2026","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0725","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00128","article-title":"CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment","volume":"10","author":"Martinez","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0730","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13045-021-01170-7","article-title":"A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma","volume":"14","author":"Mei","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0735","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s10238-023-01020-5","article-title":"RNA modification in mRNA cancer vaccines","volume":"23","author":"Mei","year":"2023","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0740","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz8235","article-title":"Strong vaccine responses during chemotherapy are associated with prolonged cancer survival","volume":"12","author":"Melief","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0745","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202515130","article-title":"Fusion peptide-incorporated lipid nanoparticles boost endosomal escape and enhance cytosolic mRNA delivery","volume":"38","author":"Meng","year":"2026","journal-title":"Adv. Mater."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0750","article-title":"Antigen presenting cell mimetic lipid nanoparticles for rapid mRNA CAR T cell cancer immunotherapy","volume":"36","author":"Metzloff","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0755","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1080\/1744666X.2024.2334258","article-title":"What is the relevance of FoxP3 in the tumor microenvironment and cancer outcomes?","volume":"20","author":"Meyiah","year":"2024","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0760","doi-asserted-by":"crossref","DOI":"10.1002\/advs.201801847","article-title":"Emerging nano\u2212\/microapproaches for cancer immunotherapy","volume":"6","author":"Mi","year":"2019","journal-title":"Adv. Sci."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0765","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1188049","article-title":"From bench to bedside: the history and progress of CAR T cell therapy","volume":"14","author":"Mitra","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0770","article-title":"Memory programming and new manufacturing paradigms in CAR-T cell therapy","volume":"1\u201314","author":"Mohammadkhani","year":"2026","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0775","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.867013","article-title":"The past, present, and future of non-viral CAR T cells","volume":"13","author":"Moretti","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0780","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01965","article-title":"Use of cell and genome modification technologies to generate improved \u201coff-the-shelf\u201d CAR T and CAR NK cells","volume":"11","author":"Morgan","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0785","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0790","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0795","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.5_suppl.TPS610","article-title":"INTerpath-004: a phase 2, randomized, double-blind study of adjuvant pembrolizumab (pembro) with V940 (mRNA-4157) or placebo for renal cell carcinoma (RCC)","volume":"43","author":"Motzer","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0800","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2020.00410","article-title":"Engineering CAR T cells to target the HIV reservoir","volume":"10","author":"Mu","year":"2020","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0805","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/d41573-024-00150-z","article-title":"In vivo CAR T cells move into clinical trials","volume":"23","author":"Mullard","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0810","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15221","article-title":"Induction of resident memory T cells enhances the efficacy of cancer vaccine","volume":"8","author":"Nizard","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0815","article-title":"The therapeutic potential of circular RNAs","volume":"1\u201315","author":"O\u2019Leary","year":"2025","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0820","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O\u2019Rourke","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0825","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.xphs.2022.11.001","article-title":"The storage and in-use stability of mRNA vaccines and therapeutics: not a cold case","volume":"112","author":"Oude Blenke","year":"2023","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0830","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2024-CT051","article-title":"Abstract CT051: preliminary results from LuCa-MERIT-1, a first-in-human phase I trial evaluating the fixed antigen mRNA vaccine BNT116 + docetaxel in patients with advanced non-small cell lung cancer","volume":"84","author":"\u00d6ven","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0835","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/s41467-024-55137-6","article-title":"Branched endosomal disruptor (BEND) lipids mediate delivery of mRNA and CRISPR-Cas9 ribonucleoprotein complex for hepatic gene editing and T cell engineering","volume":"16","author":"Padilla","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0840","doi-asserted-by":"crossref","first-page":"14366","DOI":"10.1038\/s41598-017-14749-3","article-title":"Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity","volume":"7","author":"Park","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0845","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2518820123","article-title":"Computational design of HLA class I superbinders for broad T cell immunogenicity","volume":"123","author":"Peer","year":"2026","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0850","doi-asserted-by":"crossref","first-page":"40293","DOI":"10.1021\/acsnano.5c11721","article-title":"Endosomal escape of lipid nanoparticles: a perspective on the literature data","volume":"19","author":"Pei","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0855","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","article-title":"CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors","volume":"21","author":"Peng","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0860","article-title":"Sensitization of tumours to immunotherapy by boosting early type-I interferon responses enables epitope spreading","volume":"1\u201316","author":"Qdaisat","year":"2025","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0865","article-title":"Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician\u2019s choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial","volume":"0","author":"Qi","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0870","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2021.107760","article-title":"Non-viral transfection technologies for next-generation therapeutic T cell engineering","volume":"49","author":"Raes","year":"2021","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0875","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell Therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0880","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1186\/s12951-022-01476-9","article-title":"Nanoparticles mediated tumor microenvironment modulation: current advances and applications","volume":"20","author":"Raju","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0885","article-title":"A CAR enhancer increases the activity and persistence of CAR T cells","volume":"1\u201312","author":"Rakhshandehroo","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0890","series-title":"Improving Outcomes and Mitigating Costs Associated With CAR T-Cell Therapy. Optimizing the Value of CAR T-Cell Therapy: Managed Care Considerations From Recent Clinical Findings","first-page":"27","author":"Rebecca Borgert","year":"2021"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0895","first-page":"1","article-title":"CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial","author":"Reiss","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0900","series-title":"FDA D.I.S.C.O. Burst Edition: FDA Approval of ABECMA (Idecabtagene Vicleucel) the First FDA Approved cell-Based Gene Therapy for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma","author":"Research, C. for D.E","year":"2021"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0905","unstructured":"Research, C. for D.E. and, 2022a. FDA D.I.S.C.O. Burst Edition: FDA Approval of Breyanzi (lisocabtagene maraleucel) for Second-line Treatment of Large B-cell Lymphoma. FDA."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0910","unstructured":"Research, C. for D.E. 2022b. FDA D.I.S.C.O. Burst Edition: FDA Approval of CARVYKTI (ciltacabtagene autoleucel) for the Treatment of Adult Patients with Relapsed or refractory multiple Myeloma After Four or More Prior Lines of Therapy, Including a Proteasome Inhibitor, an Immunomodulatory Agent, and an Anti-CD38 Monoclonal Antibody. FDA."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0915","series-title":"FDA Approves Obecabtagene Autoleucel for Adults with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia","author":"Research, C. for D.E","year":"2024"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0920","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41417-021-00359-9","article-title":"Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy","volume":"29","author":"Rezaei","year":"2022","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0925","author":"Rituximab"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0930","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/s41587-022-01491-z","article-title":"Unlocking the promise of mRNA therapeutics","volume":"40","author":"Rohner","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0935","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0940","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1126\/science.aar7112","article-title":"Personalized vaccines for cancer immunotherapy","volume":"359","author":"Sahin","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0945","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0950","first-page":"1","article-title":"Individualized mRNA vaccines evoke durable T cell immunity in adjuvant TNBC","author":"Sahin","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0955","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0960","first-page":"1","article-title":"RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer","author":"Sethna","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0965","doi-asserted-by":"crossref","DOI":"10.3389\/frtra.2023.1238535","article-title":"Promises and challenges of a decentralized CAR T-cell manufacturing model","volume":"2","author":"Shah","year":"2023","journal-title":"Front. Transplant."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0970","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/bloodadvances.2019000219","article-title":"Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy","volume":"3","author":"Shah","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0975","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1126\/science.adx4381","article-title":"Sex differences in tissue-specific immunity and immunology","volume":"389","author":"Sharma","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.biotechadv.2026.108942_bb0980","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ymthe.2020.09.038","article-title":"Personalized cancer vaccines: clinical landscape, challenges, and opportunities","volume":"29","author":"Shemesh","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0985","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1038\/s41467-024-47801-8","article-title":"Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed\/refractory multiple myeloma: a phase I\/II trial","volume":"15","author":"Shi","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0990","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-023-01383-x","article-title":"Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies","volume":"8","author":"Shi","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.biotechadv.2026.108942_bb0995","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13046-017-0509-1","article-title":"Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer","volume":"36","author":"Shindo","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.biotechadv.2026.108942_bb1000","first-page":"317","article-title":"CD4+ T cells in cancer","volume":"4","author":"Speiser","year":"2023","journal-title":"Nat. Can."},{"key":"10.1016\/j.biotechadv.2026.108942_bb1005","article-title":"Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers","volume":"1\u20137","author":"Steffin","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.biotechadv.2026.108942_bb1010","doi-asserted-by":"crossref","first-page":"5638","DOI":"10.7150\/jca.34471","article-title":"Histone deacetylase inhibition up-regulates MHC class I to facilitate cytotoxic T lymphocyte-mediated tumor cell killing in glioma cells","volume":"10","author":"Sun","year":"2019","journal-title":"J. Cancer"},{"key":"10.1016\/j.biotechadv.2026.108942_bb1015","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101427","article-title":"mRNA-LNP vaccine strategies: effects of adjuvants on non-parenchymal liver cells and tolerance","volume":"33","author":"Svensson","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.biotechadv.2026.108942_bb1020","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1433185","article-title":"Nucleic acid cancer vaccines targeting tumor related angiogenesis. Could mRNA vaccines constitute a game changer?","volume":"15","author":"Tadic","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb1025","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","article-title":"Teaching an old dog new tricks: next-generation CAR T cells","volume":"120","author":"Tokarew","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biotechadv.2026.108942_bb1030","author":"Tontonoz"},{"key":"10.1016\/j.biotechadv.2026.108942_bb1035","series-title":"Dendritic Cell Vaccines Extend CD19 CAR-T Cell Persistence and Improve the Outcomes in Refractory\/Relapsed Adult B-ALL. Blood, 65th ASH Annual Meeting Abstracts","first-page":"3488","volume":"142","author":"Tu","year":"2023"},{"key":"10.1016\/j.biotechadv.2026.108942_bb1040","doi-asserted-by":"crossref","first-page":"50708","DOI":"10.1021\/acsami.2c08619","article-title":"Nanomaterials for natural killer cell-based Immunoimaging and immunotherapies in cancer","volume":"15","author":"Uthaman","year":"2023","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.biotechadv.2026.108942_bb1045","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00008","article-title":"Vaccine strategies to improve anti-cancer cellular immune responses","volume":"10","author":"Vermaelen","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb1050","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1548292","article-title":"ADCC: the rock band led by therapeutic antibodies, tumor and immune cells","volume":"16","author":"Vincken","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb1055","article-title":"Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results","volume":"1\u20136","author":"Wainberg","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.biotechadv.2026.108942_bb1060","author":"Waldron"},{"key":"10.1016\/j.biotechadv.2026.108942_bb1065","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.667","article-title":"Circular RNA-based neoantigen vaccine for hepatocellular carcinoma immunotherapy","volume":"5","author":"Wang","year":"2024","journal-title":"MedComm"},{"key":"10.1016\/j.biotechadv.2026.108942_bb1070","doi-asserted-by":"crossref","first-page":"11149","DOI":"10.1002\/cam4.5698","article-title":"Role of tumor microenvironment in cancer progression and therapeutic strategy","volume":"12","author":"Wang","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.biotechadv.2026.108942_bb1075","first-page":"1","article-title":"Breakthrough of solid tumor treatment: CAR-NK immunotherapy","volume":"10","author":"Wang","year":"2024","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.biotechadv.2026.108942_bb1080","article-title":"Understanding of endo\/lysosomal escape of nanomaterials in biomedical application","volume":"3","author":"Wang","year":"2025","journal-title":"Smart Mol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb1085","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1021\/acsnano.6b08731","article-title":"Tumor-penetrating nanoparticles for enhanced anticancer activity of combined photodynamic and hypoxia-activated Therapy","volume":"11","author":"Wang","year":"2017","journal-title":"ACS Nano"},{"key":"10.1016\/j.biotechadv.2026.108942_bb1090","first-page":"1","article-title":"CAR-T therapy dilemma and innovative design strategies for next generation","volume":"16","author":"Wang","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.biotechadv.2026.108942_bb1095","doi-asserted-by":"crossref","DOI":"10.1002\/elsc.70067","article-title":"Process systems engineering in precision medicine: opportunities in autologous CAR-T Therapy","volume":"26","author":"Wayne Bequette","year":"2026","journal-title":"Eng. Life Sci."},{"key":"10.1016\/j.biotechadv.2026.108942_bb1100","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.biotechadv.2026.108942_bb1105","doi-asserted-by":"crossref","first-page":"5899","DOI":"10.3390\/ijms22115899","article-title":"CAR-NK cells in the treatment of solid tumors","volume":"22","author":"Wrona","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biotechadv.2026.108942_bb1110","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.3390\/pharmaceutics14101990","article-title":"Nanoparticle-based drug delivery systems targeting tumor microenvironment for cancer immunotherapy resistance: current advances and applications","volume":"14","author":"Wu","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biotechadv.2026.108942_bb1115","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.3390\/cancers14133230","article-title":"Current status and perspectives of dual-targeting chimeric antigen receptor T-cell therapy for the treatment of hematological malignancies","volume":"14","author":"Xie","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.biotechadv.2026.108942_bb1120","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1076883","article-title":"Advances in artificial intelligence to predict cancer immunotherapy efficacy","volume":"13","author":"Xie","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb1125","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.809754","article-title":"In-vivo induced CAR-T cell for the potential breakthrough to overcome the barriers of current CAR-T cell therapy","volume":"12","author":"Xin","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb1130","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0140-6736(25)01030-X","article-title":"In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma","volume":"406","author":"Xu","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.biotechadv.2026.108942_bb1135","doi-asserted-by":"crossref","DOI":"10.1016\/j.jare.2026.01.070","article-title":"Biomimetic and personalized nanovaccines in cancer immunotherapy: design innovations, translational challenges, and future directions","author":"Xu","year":"2026","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.biotechadv.2026.108942_bb1140","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40164-023-00373-7","article-title":"Current advances and challenges in CAR T-cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment","volume":"12","author":"Yan","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb1145","article-title":"Allogeneic anti-CD19 CAR-T cells induce remission in refractory systemic lupus erythematosus","volume":"1\u20133","author":"Yang","year":"2025","journal-title":"Cell Res."},{"key":"10.1016\/j.biotechadv.2026.108942_bb1150","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1211262","article-title":"Research progress of nanovaccine in anti-tumor immunotherapy","volume":"13","author":"Yao","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb1155","first-page":"25","article-title":"Design and application of oncolytic viruses for cancer immunotherapy","volume":"65","author":"Yl\u00f6sm\u00e4ki","year":"2020","journal-title":"Curr. Opin. Biotechnol. Chem. Biotechnol. Pharm. Biotechnol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb1160","article-title":"Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data","volume":"1\u201312","author":"Yoo","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.biotechadv.2026.108942_bb1165","doi-asserted-by":"crossref","DOI":"10.1021\/acsnano.4c15765","article-title":"Cancer Nanovaccines: mechanisms, design principles, and clinical translation","author":"Zaccariotto","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.biotechadv.2026.108942_bb1170","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1038\/s41467-020-16160-5","article-title":"Systematically optimized BCMA\/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma","volume":"11","author":"Zah","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biotechadv.2026.108942_bb1175","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41568-025-00820-z","article-title":"Recent advances in therapeutic cancer vaccines","volume":"25","author":"Zaidi","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biotechadv.2026.108942_bb1180","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","article-title":"Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL","volume":"609","author":"Zhang","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.biotechadv.2026.108942_bb1185","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.ccell.2022.09.013","article-title":"Depletion of BATF in CAR-T cells enhances antitumor activity by inducing resistance against exhaustion and formation of central memory cells","volume":"40","author":"Zhang","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biotechadv.2026.108942_bb1190","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1559","article-title":"Nanovaccines for cancer immunotherapy","volume":"11","author":"Zhang","year":"2019","journal-title":"WIREs Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb1195","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/imm.70094","article-title":"Barriers and strategies to enhance CAR-T cell infiltration in solid Tumours: a systematic review","volume":"178","author":"Zhang","year":"2026","journal-title":"Immunology"},{"key":"10.1016\/j.biotechadv.2026.108942_bb1200","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13045-018-0677-2","article-title":"Universal CARs, universal T cells, and universal CAR T cells","volume":"11","author":"Zhao","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb1205","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","article-title":"Vaccine adjuvants: mechanisms and platforms","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.biotechadv.2026.108942_bb1210","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1022808","article-title":"IL-7: a promising adjuvant ensuring effective T cell responses and memory in combination with cancer vaccines?","volume":"13","author":"Zhao","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biotechadv.2026.108942_bb1215","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1158\/0008-5472.CAN-22-2220","article-title":"Tumor-derived small extracellular vesicles inhibit the efficacy of CAR T cells against solid tumors","volume":"83","author":"Zhong","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.biotechadv.2026.108942_bb1220","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3390\/biomedicines9010059","article-title":"Application of CAR-T cell Therapy beyond oncology: autoimmune diseases and viral infections","volume":"9","author":"Zmievskaya","year":"2021","journal-title":"Biomedicines"}],"container-title":["Biotechnology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0734975026001485?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0734975026001485?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T02:27:03Z","timestamp":1783477623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0734975026001485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":238,"alternative-id":["S0734975026001485"],"URL":"https:\/\/doi.org\/10.1016\/j.biotechadv.2026.108942","relation":{},"ISSN":["0734-9750"],"issn-type":[{"value":"0734-9750","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR-T cells and cancer nanovaccines: Comparative insights into advances and translational challenges","name":"articletitle","label":"Article Title"},{"value":"Biotechnology Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biotechadv.2026.108942","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108942"}}